Phase 3, open-label trial of pneumococcal 13-valent CRM197 vaccine conjugate [Prevnar 13] in children aged 5-10 years who had previously been vaccinated for the prevention of pneumococcal disease with pneumococcal 7-valent CRM197 vaccine conjugate [Prevnar], and vaccine-naive children and adolescents aged 10-17 years

Trial Profile

Phase 3, open-label trial of pneumococcal 13-valent CRM197 vaccine conjugate [Prevnar 13] in children aged 5-10 years who had previously been vaccinated for the prevention of pneumococcal disease with pneumococcal 7-valent CRM197 vaccine conjugate [Prevnar], and vaccine-naive children and adolescents aged 10-17 years

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2013

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
  • Indications Pneumococcal infections
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 14 Mar 2012 New trial record
    • 12 Mar 2012 Results published in a Pfizer media release and presented at the 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top